Chronic cystamine treatment inhibits small artery remodelling in rats

被引:32
作者
Eftekhari, Ashkan
Rahman, Awahan
Schaebel, Louise Holm
Chen, Hua
Rasmussen, Claus Vitrup
Aalkjaer, Christian
Buus, Carsten Leander
Mulvany, Michael J.
机构
[1] Aarhus Univ, Dept Pharmacol, DK-8000 Aarhus, Denmark
[2] Aarhus Univ, Dept Physiol, DK-8000 Aarhus, Denmark
关键词
remodelling; hypertension; cystamine; tissue transglutaminase;
D O I
10.1159/000106465
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Background/ Aims: We investigated whether the tissue transglutaminase inhibitor cystamine is able to inhibit remodelling of small arteries in vivo, a possibility suggested by recent in vitro experiments. Methods: Using osmotic mini-pumps, phenylephrine, cystamine and/or amlodipine were infused for 1-2 weeks into 9-week-old Wistar rats. Small arteries were then removed for pressure myograph investigation. Results: Phenylephrine infusion caused inward remodelling of the small arteries compared to vehicle infusion. The remodelling was abolished by concomitant infusion with cystamine; blood pressure was unaffected. Second, we investigated whether cystamine was able to inhibit outward remodelling. Rats were first infused with phenylephrine for 1 week, and some were infused for a further week with amlodipine with or without cystamine. Amlodipine caused 24% outward remodelling compared to vessels from rats at completion of the phenylephrine infusion. The outward remodelling was attenuated 86% by concomitant cystamine infusion. A series of in vitro experiments supported the inhibitory action of cystamine on tissue transglutaminase. Conclusion: The ability of cystamine to inhibit inward remodelling independent of blood pressure is consistent with a role of tissue transgluaminase in this process. It remains to be determined if the ability of cystamine to inhibit outward remodelling also involves inhibition of tissue transglutaminase. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:471 / 482
页数:12
相关论文
共 46 条
[1]   Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice [J].
Agah, A ;
Kyriakides, TR ;
Bornstein, P .
AMERICAN JOURNAL OF PATHOLOGY, 2005, 167 (01) :81-88
[2]  
Bailey CDC, 2005, PROG EXP TUMOR RES, V38, P139
[3]   The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase [J].
Bailey, Craig D. C. ;
Johnson, Gail V. W. .
NEUROBIOLOGY OF AGING, 2006, 27 (06) :871-879
[4]   Small artery remodeling depends on tissue-type transglutaminase [J].
Bakker, ENTP ;
Buus, CL ;
Spaan, JAE ;
Perree, J ;
Ganga, A ;
Rolf, TM ;
Sorop, O ;
Bramsen, LH ;
Mulvany, MJ ;
VanBavel, E .
CIRCULATION RESEARCH, 2005, 96 (01) :119-126
[5]   Remodeling of resistance arteries in organoid culture is modulated by pressure and pressure pulsation and depends on vasomotion [J].
Bakker, ENTP ;
Sorop, O ;
Spaan, JAE ;
VanBavel, E .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 286 (06) :H2052-H2056
[6]   Activation of resistance arteries with endothelin-1: From vasoconstriction to functional adaptation and remodeling [J].
Bakker, ENTP ;
Buus, CL ;
VanBavel, E ;
Mulvany, MJ .
JOURNAL OF VASCULAR RESEARCH, 2004, 41 (02) :174-182
[7]   Inward remodeling follows chronic vasoconstriction in isolated resistance arteries [J].
Bakker, ENTP ;
van der Meulen, ET ;
van den Berg, BM ;
Everts, V ;
Spaan, JAE ;
VanBavel, E .
JOURNAL OF VASCULAR RESEARCH, 2002, 39 (01) :12-20
[8]  
Bakker ENTP, 2000, AM J PHYSIOL-HEART C, V278, pH1233
[9]   Flow-dependent remodeling of small arteries in mice deficient for tissue-type transglutaminase - Possible compensation by macrophage-derived factor XIII [J].
Bakker, Erik N. T. P. ;
Pistea, Adrian ;
Spaan, Jos A. E. ;
Rolf, Titia ;
de Vries, Carlie J. ;
van Rooijen, Nico ;
Candi, Eleonara ;
VanBavel, Ed .
CIRCULATION RESEARCH, 2006, 99 (01) :86-92
[10]   Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase [J].
Borrell-Pagès, M ;
Canals, JM ;
Cordelières, FP ;
Parker, JA ;
Pineda, JR ;
Grange, G ;
Bryson, EA ;
Guillermier, M ;
Hirsch, E ;
Hantraye, P ;
Cheetham, ME ;
Néri, C ;
Alberch, J ;
Brouillet, E ;
Saudou, F ;
Humbert, S .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (05) :1410-1424